Skip to main content

Advertisement

SpringerLink
Log in

CSF sAPPα and sAPPβ levels in Alzheimer’s Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis

  • Original Paper
  • Published:
NeuroMolecular Medicine Aims and scope Submit manuscript

Abstract

The soluble amyloid protein procurer α (sAPPα) and β (sAPPβ) have been postulated as promising new cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and multiple other neurodegenerative diseases, but have failed to meet expectations with their often discordant and even contradictory findings to date. The aim of the study was to systematically explore this issue. Cochrane Library, PubMed, and CNKI were systematically searched without language or date restrictions. This network meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and also adhered to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. Twenty studies, comprising ten groups, were eligible and included. Overall, 19 eligible studies with 1634 patients contributed to the analysis of CSF sAPPα levels and 16 eligible studies with 1684 patients contributed to the analysis of CSF sAPPβ levels. CSF sAPPβ levels are significantly higher in AD than in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP); higher in Control than in Depression, CBS and PSP; higher in Parkinson’s disease dementia (PDD) than in CBS and PSP; higher in mild cognitive impairment progressed to AD dementia during the follow-up period (pMCI) than in Depression and PSP; higher in stable mild cognitive impairment (sMCI) than in Depression. With regard to CSF sAPPα levels, there were no significant difference among groups. However, surprisingly, the resultant rankings graphically showed that pMCI populations have the highest levels of CSF sAPPα and sAPPβ. Furthermore, it seemed there was a positive correlation between CSF sAPPα and sAPPβ levels. The measurement of CSF sAPPα and sAPPβ levels may provide an alternative method for the diagnosis of early-stage AD, pMCI, which is conducive to preventive therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

All data of the articles included in our research had been published online and are available to investigators.

Abbreviations

AD:

Alzheimer’s disease

CBS:

Corticobasal syndrome

CSF:

Cerebrospinal fluid

DLB:

Dementia with Lewy bodies

FTD:

Frontotemporal dementia

NMA:

Network meta-analysis

PDD:

Parkinson’s disease dementia

pMCI:

Mild cognitive impairment progressed to AD dementia during the follow-up period

PSP:

Progressive supranuclear palsy

sAPPα:

Soluble amyloid protein procurer α

sAPPβ:

Soluble amyloid protein procurer β

sMCI:

Stable mild cognitive impairment

VaD:

Vascular dementia

References

  • Alcolea, D., Vilaplana, E., Suárez-Calvet, M., Illán-Gala, I., Blesa, R., Clarimón, J., et al. (2017). CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology,89(2), 178–188.

    CAS  PubMed  Google Scholar 

  • Alexopoulos, P., Tsolakidou, A., Roselli, F., Arnold, A., Grimmer, T., Westerteicher, C., et al. (2012). Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimer’s and Dementia,8(4), 304–311.

    CAS  PubMed  Google Scholar 

  • Araki, W., Hattori, K., Kanemaru, K., Yokoi, Y., Omachi, Y., Takano, H., et al. (2017). Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders. Biomarker Research,5, 28.

    PubMed  PubMed Central  Google Scholar 

  • Cheng, X., He, P., Lee, T., Yao, H., Li, R., & Shen, Y. (2014). High activities of BACE1 in brains with mild cognitive impairment. The American Journal of Pathology,184(1), 141–147.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chow, V. W., Mattson, M. P., Wong, P. C., & Gleichmann, M. (2010). An overview of APP processing enzymes and products. NeuroMolecular Medicine,12(1), 1–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cuchillo-Ibañez, I., Lopez-Font, I., Boix-Amorós, A., Brinkmalm, G., Blennow, K., Molinuevo, J. L., et al. (2015). Heteromers of amyloid precursor protein in cerebrospinal fluid. Molecular Neurodegeneration,10, 2.

    PubMed  PubMed Central  Google Scholar 

  • Deng, J., Habib, A., Obregon, D. F., Barger, S. W., Giunta, B., Wang, Y. J., et al. (2015). Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3β signaling pathway. Journal of Neurochemistry,135(3), 630–637.

    CAS  PubMed  PubMed Central  Google Scholar 

  • de Leon, M. J., DeSanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., et al. (2004). MRI and CSF studies in the early diagnosis of Alzheimer’s disease. Journal of Internal Medicine,256(3), 205–223.

    PubMed  Google Scholar 

  • DerSimonian, R., & Laird, N. (2015). Meta-analysis in clinical trials revisited. Contemporary Clinical Trials,45(Pt A), 139–145.

    PubMed  PubMed Central  Google Scholar 

  • Efthimiopoulos, S., Vassilacopoulou, D., Ripellino, J. A., Tezapsidis, N., & Robakis, N. K. (1996). Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proceedings of the National academy of Sciences of the United States of America,93(15), 8046–8050.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fellgiebel, A., Kojro, E., Müller, M. J., Scheurich, A., Schmidt, L. G., & Fahrenholz, F. (2009). CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer’s type. Journal of Geriatric Psychiatry and Neurology,22(1), 3–9.

    PubMed  Google Scholar 

  • Furukawa, K., Sopher, B. L., Rydel, R. E., Begley, J. G., Pham, D. G., Martin, G. M., et al. (1996). Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. Journal of Neurochemistry,67(5), 1882–1896.

    CAS  PubMed  Google Scholar 

  • Gabelle, A., Roche, S., Gény, C., Bennys, K., Labauge, P., Tholance, Y., et al. (2010). Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Research,1357, 175–183.

    CAS  PubMed  Google Scholar 

  • Gabelle, A., Roche, S., Gény, C., Bennys, K., Labauge, P., Tholance, Y., et al. (2011). Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. Journal of Alzheimer’s Disease,26(3), 553–563.

    CAS  PubMed  Google Scholar 

  • GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet,388(10053), 1545–1602.

    Google Scholar 

  • GBD 2015 Mortality and Causes of Death Collaborators. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet,388(10053), 1459–1544.

    Google Scholar 

  • GBD 2016 Causes of Death Collaborators. (2017). Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet,390(10100), 1151–1210.

    Google Scholar 

  • GBD 2016 Dementia Collaborators. (2019). Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology,18(1), 88–106.

    Google Scholar 

  • Habib, A., Sawmiller, D., & Tan, J. (2017). Restoring soluble amyloid precursor protein α functions as a potential treatment for alzheimer’s disease. Journal of Neuroscience Research,95(4), 973–991.

    CAS  PubMed  Google Scholar 

  • Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer’s disease: A clinical follow-up study of 4.7 years. Journal of Alzheimer’s Disease 21(4):1119–1128

    CAS  PubMed  Google Scholar 

  • Kantarci, K., Weigand, S. D., Petersen, R. C., Boeve, B. F., Knopman, D. S., Gunter, J., et al. (2007). Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer’s disease. Neurobiology of Aging,28(9), 1330–1339.

    CAS  PubMed  Google Scholar 

  • Kodamullil, A. T., Zekri, F., Sood, M., Hengerer, B., Canard, L., McHale, D., et al. (2017). Trial watch: Tracing investment in drug development for Alzheimer disease. Nature Reviews Drug Discovery,16(12), 819.

    CAS  PubMed  Google Scholar 

  • Lannfelt, L., Basun, H., Wahlund, L. O., Rowe, B. A., & Wagner, S. L. (1995). Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer’s disease. Nature Medicine,1(8), 829–832.

    CAS  PubMed  Google Scholar 

  • Lewczuk, P., Kamrowski-Kruck, H., Peters, O., Heuser, I., Jessen, F., Popp, J., et al. (2010). Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Molecular Psychiatry,15(2), 138–145.

    CAS  PubMed  Google Scholar 

  • Lewczuk, P., Popp, J., Lelental, N., Kölsch, H., Maier, W., Kornhuber, J., et al. (2012). Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer’s disease. Journal of Alzheimer’s Disease,28(1), 119–125.

    CAS  PubMed  Google Scholar 

  • Magdalinou, N. K., Paterson, R. W., Schott, J. M., Fox, N. C., Mummery, C., Blennow, K., et al. (2015). A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry,86(11), 1240–1247.

    CAS  PubMed  Google Scholar 

  • Miyajima, M., Nakajima, M., Ogino, I., Miyata, H., Motoi, Y., & Arai, H. (2013). Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus. European Journal of Neurology,20(2), 236–242.

    CAS  PubMed  Google Scholar 

  • Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ,339, b2535.

    PubMed  PubMed Central  Google Scholar 

  • Moriya, M., Miyajima, M., Nakajima, M., Ogino, I., & Arai, H. (2015). Impact of cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus on the amyloid cascade. PLoS ONE,10(3), e0119973.

    PubMed  PubMed Central  Google Scholar 

  • Mulugeta, E., Londos, E., Hansson, O., Ballard, C., Skogseth, R., Minthon, L., et al. (2011). Cerebrospinal fluid levels of sAPPα and sAPPβ in lewy body and alzheimer’s disease: Clinical and neurochemical correlates. International Journal of Alzheimer’s Disease,2011, 495025.

    PubMed  PubMed Central  Google Scholar 

  • Nhan, H. S., Chiang, K., & Koo, E. H. (2015). The multifaceted nature of amyloid precursor protein and its proteolytic fragments: Friends and foes. Acta Neuropathologica,129(1), 1–19.

    CAS  PubMed  Google Scholar 

  • Nikolaev, A., McLaughlin, T., O’Leary, D. D., & Tessier-Lavigne, M. (2009). APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature,457(7232), 981–989.

    CAS  PubMed  PubMed Central  Google Scholar 

  • O’Brien, R. J., & Wong, P. C. (2011). Amyloid precursor protein processing and Alzheimer’s disease. Annual Review of Neuroscience,34, 185–204.

    PubMed  PubMed Central  Google Scholar 

  • Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., et al. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. The Lancet. Neurology,15(7), 673–684.

    CAS  PubMed  Google Scholar 

  • Perneczky, R., Alexopoulos, P., & Kurz, A. (2014). Soluble amyloid precursor proteins and secretases as Alzheimer’s disease biomarkers. Trends in Molecular Medicine,20(1), 8–15.

    CAS  PubMed  Google Scholar 

  • Perneczky, R., Tsolakidou, A., Arnold, A., Diehl-Schmid, J., Grimmer, T., Förstl, H., et al. (2011). CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology,77(1), 35–38.

    CAS  PubMed  Google Scholar 

  • Peskind, E. R., Leverenz, J., Farlow, M. R., Ito, R. K., Provow, S. A., Siegel, R. S., et al. (1997). Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls. Alzheimer Disease and Associated Disorders,11(4), 201–206.

    CAS  PubMed  Google Scholar 

  • Popp, J., Lewczuk, P., Kölsch, H., Meichsner, S., Maier, W., Kornhuber, J., et al. (2012). Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer’s disease. Journal of Neurochemistry,123(2), 310–316.

    CAS  PubMed  Google Scholar 

  • Post, A., Ackl, N., Rücker, M., Schreiber, Y., Binder, E. B., Ising, M., et al. (2006). Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression. Biological Psychiatry,59(9), 858–862.

    PubMed  Google Scholar 

  • Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. (2000) Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012

  • Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., et al. (2006). Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proceedings of the National academy of Sciences of the United States of America,103(2), 443–448.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Steinacker, P., Hendrich, C., Sperfeld, A. D., Jesse, S., Lehnert, S., Pabst, A., et al. (2009). Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Journal of Neural Transmission,116(9), 1169–1178.

    CAS  PubMed  Google Scholar 

  • Tamagno, E., Parola, M., Bardini, P., Piccini, A., Borghi, R., Guglielmotto, M., et al. (2005). Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. Journal of Neurochemistry,92(3), 628–636.

    CAS  PubMed  Google Scholar 

  • Tarkowski, E., Andreasen, N., Tarkowski, A., & Blennow, K. (2003). Intrathecal inflammation precedes development of Alzheimer’s disease. Journal of Neurology, Neurosurgery and Psychiatry,74(9), 1200–1205.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Taverna, M., Straub, T., Hampel, H., Rujescu, D., & Lichtenthaler, S. F. (2013). A new sandwich immunoassay for detection of the α-secretase cleaved, soluble amyloid-β protein precursor in cerebrospinal fluid and serum. Journal of Alzheimer’s disease,37(4), 667–678.

    CAS  PubMed  Google Scholar 

  • Tezapsidis, N., Li, H. C., Ripellino, J. A., Efthimiopoulos, S., Vassilacopoulou, D., Sambamurti, K., et al. (1998). Release of nontransmembrane full-length Alzheimer’s amyloid precursor protein from the lumenar surface of chromaffin granule membranes. Biochemistry,37(5), 1274–1282.

    CAS  PubMed  Google Scholar 

  • Tsolakidou, A., Alexopoulos, P., Guo, L. H., Grimmer, T., Westerteicher, C., Kratzer, M., et al. (2013). β-Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau. Alzheimer’s and Dementia,9(4), 386–391.

    PubMed  Google Scholar 

  • van Waalwijk van Doorn, L. J., Koel-Simmelink, M. J., Haußmann, U., Klafki, H., Struyfs, H., Linning, P., et al. (2016). Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. Journal of Neurochemistry,137(1), 112–121.

    CAS  PubMed  Google Scholar 

  • Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. (2011) Tugwell The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [online]. The Ottawa Hospital Rresearch Institute. Available at: http://www.ohri.ca/programs/clinical epidemiology/oxford.asp. Accessed May 2, 2019.

  • Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., et al. (2008). Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Archives of Neurology,65(8), 1102–1107.

    PubMed  Google Scholar 

Download references

Acknowledgments

This work was funded in part by the Anhui Provincial Natural Science Foundation, Key Research and Development Plan “A” (Grant Numbers 1804h08020236); the Key Project of University Natural Science Foundation of Anhui Province (Grant Numbers KJ2018A0206).

Funding

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Author information

Author notes

  1. Tang, W. and Wang, Y. contributed equally to this work.

Authors and Affiliations

  1. Department of Laboratory Medicine, The Second Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, 230601, Anhui, China

    Wei Tang, Juan Cheng, Jie Yao, Qiang Zhou & Shi-He Guan

  2. Department of General Surgery, The Second Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, 230601, Anhui, China

    Yan Wang

  3. Department of Clinical Laboratory Medicine, School of Public Health, Anhui Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, China

    Yu-You Yao

Authors
  1. Wei Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jie Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-You Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qiang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shi-He Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shi-He Guan.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

Ethical Approval

The manuscript is a retrospective report that does not require ethics committee approval at our institution.

Informed Consent

Written informed consent was obtained from all participants involved in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 43 kb)

Supplementary material 2 (PDF 4188 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, W., Wang, Y., Cheng, J. et al. CSF sAPPα and sAPPβ levels in Alzheimer’s Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis. Neuromol Med 22, 45–55 (2020). https://doi.org/10.1007/s12017-019-08561-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12017-019-08561-7

Keywords

Search

Navigation